Assistant Professor, Medicine, Oregon Health and Science University School of Medicine
Internal Medicine
Dr. Radko Komers, MD
|
|
Give Review
Radko Komers, MD is an expert in the field of Internal Medicine. He received 1 awards: "CMS Meaningful Use Stage 1 Certification". Radko Komers is a published doctor as well. He has 60 publications published. The latest was: Thiazolidinediones--tools for the research of metabolic syndrome X. He is registered with Medicare and accepts Medicare payments.
Publications
- Rho kinase inhibition in diabetic kidney disease.
- Renin inhibition in the treatment of diabetic kidney disease.
- Epigenetic changes in renal genes dysregulated in mouse and rat models of type 1 diabetes.
- Enhanced phosphorylation of Na(+)-Cl- co-transporter in experimental metabolic syndrome: role of insulin.
- Transcriptome-Based Analysis of Kidney Gene Expression Changes Associated with Diabetes in OVE26 Mice, in the Presence and Absence of Losartan Treatment.
- 2-HYDROXYESTRADIOL SLOWS PROGRESSION OF EXPERIMENTAL POLYCYSTIC KIDNEY DISEASE.
- Microplate-based platform for combined chromatin and DNA methylation immunoprecipitation assays.
- Suppression of microRNA-29 Expression by TGF-?1 Promotes Collagen Expression and Renal Fibrosis.
- The increased activity of liver lysosomal lipase in nonalcoholic Fatty liver disease contributes to the development of hepatic insulin resistance.
- A polymorphism in the cyclooxygenase 2 gene in type 1 diabetic patients with nephropathy.
- Rho kinase inhibition in diabetic nephropathy.
- Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure.
- Effects of systemic inhibition of Rho kinase on blood pressure and renal haemodynamics in diabetic rats.
- What is the role of renin inhibition in the treatment of diabetic kidney disease?
- Effect of orchiectomy on renal function in control and diabetic rats with chronic inhibition of nitric oxide.
- High ambient glucose augments angiotensin II-induced proinflammatory gene mRNA expression in human mesangial cells: effects of valsartan and simvastatin.
- Inhibition of the renin-angiotensin system: is more better?
- Aliskiren combined with losartan in diabetes and nephropathy.
- Determination of caveolin-1 in renal caveolar and non-caveolar fractions in experimental type 1 diabetes.
- Renal activity of Akt kinase in obese Zucker rats.
- Glomerular endothelial NOS (eNOS) expression in type 2 diabetic patients with nephropathy.
- Effects of p38 mitogen-activated protein kinase inhibition on blood pressure, renal hemodynamics, and renal vascular reactivity in normal and diabetic rats.
- Renal activity of Akt kinase in experimental Type 1 diabetes.
- Renal p38 MAP kinase activity in experimental diabetes.
- Cyclo-oxygenase-2 inhibition attenuates the progression of nephropathy in uninephrectomized diabetic rats.
- [Effects of specific cycloxygenase-2 inhibition on the renal functions of ederly patients with renal function impairment].
- Renal effects of HMG-CoA reductase inhibition in a rat model of chronic inhibition of nitric oxide synthesis.
- Altered endothelial nitric oxide synthase targeting and conformation and caveolin-1 expression in the diabetic kidney.
- Gender hormones and the progression of experimental polycystic kidney disease.
- Effect of rofecoxib on the glomerular filtration rate, proteinuria and the renin-angiotensin-aldosterone system in elderly subjects with chronic renal impairment.
- Renal cyclooxygenase-2 in obese Zucker (fatty) rats.
- Emerging role of Akt kinase/protein kinase B signaling in pathophysiology of diabetes and its complications.
- Effects of long-term inhibition of neuronal nitric oxide synthase (NOS1) in uninephrectomized diabetic rats.
- Acute effects of cyclooxygenase-2 inhibition on renal function in heterozygous ren-2-transgenic rats on normal or low sodium intake.
- Effects of ACE inhibition and AT1-receptor blockade on haemodynamic responses to L-arginine in Type 1 diabetes.
- Paradoxes of nitric oxide in the diabetic kidney.
- Cyclooxygenase-2 expression and function in renal pathophysiology.
- Endothelial-derived vasoactive mediators in polycystic kidney disease.
- Treatment of hypertension in diabetic patients with nephropathy.
- Effects of cyclooxygenase-2 (COX-2) inhibition on plasma and renal renin in diabetes.
- Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors.
- Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes.
- Therapeutic potential of ACE inhibitors for the treatment of hypertension in Type 2 diabetes.
- Optimal strategies for preventing progression of renal disease: should angiotensin converting enzyme inhibitors and angiotensin receptor blockers be used together?
- Role of neuronal nitric oxide synthase (NOS1) in the pathogenesis of renal hemodynamic changes in diabetes.
- Are angiotensin-converting enzyme inhibitors the best treatment for hypertension in type 2 diabetes?
- Effects of systemic inhibition of neuronal nitric oxide synthase in diabetic rats.
- Effect of ACE inhibition and angiotensin AT1 receptor blockade on renal and blood pressure response to L-arginine in humans.
- Effect of hyperinsulinaemia on renal function and nitrate/nitrite excretion in healthy subjects.
- Thiazolidinediones--tools for the research of metabolic syndrome X.
- Increased density of renal amylin binding sites in experimental hypertension.
- Renal sodium handling in experimental diabetes: role of NO.
- Kinins or nitric oxide, or both, are involved in the antitrophic effects of angiotensin converting enzyme inhibitors on diabetes-associated mesenteric vascular hypertr...
- [Pathophysiologic mechanisms of early changes in renal hemodynamics in diabetes mellitus].
- [Changes in blood pressure, proteinuria and renal hemodynamics in type I diabetes with manifestations of diabetic nephropathy after 2 months of captopril therapy].
- The effects of dietary cholesterol on experimental diabetic nephropathy.
- Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition.
- Role of endothelium-derived nitric oxide in the pathogenesis of the renal hemodynamic changes of experimental diabetes.
- Acute renal hemodynamic effects of ACE inhibition in diabetic hyperfiltration: role of kinins.
Doctors Specialties
- Internal Medicine
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Drug Facts
| NPI NUMBER | 1417276544 | |
| NPPES Provider LastName | KOMERS | |
| NPPES Provider FirstName | RADKO | |
| NPPES Provider ZIPCode | 972393098 | |
| NPPES Provider State | OR | |
| Specialty Description | Nephrology | |
| Total Claim Count | 229.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1417276544 |
| Last Name Of The Provider | KOMERS |
| First Name Of The Provider | RADKO |
| View All |
Similar Doctors
|
|
Dr. Sean E. Jones, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kevin R. Bruce, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brian L. Chan, MD |
|
|
Dr. Alan J. Hunter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Virgil L. Hamlin Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Petya N. Gueordjeva, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jake D. Lenington, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aruna Jayaram, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Uhng-Choon Shim, MD |